What we do Mangalam Drugs and Organics Ltd manufactures active pharmaceutical ingredients (APIs), bulk drugs, and chemical intermediates with strong R&D and WHO-approved facilities. |
Founded in 1,972 |
Market share Established player in Indian API and bulk drugs market with WHO approvals and expanding anti-malaria API portfolio. |
Problem solved Provides critical APIs and bulk drugs solving supply needs for pharmaceutical and chemical industries, reducing import dependency. |
Top clients or who we serve Serves pharmaceutical companies domestically and internationally (exports), focusing B2B model for bulk drugs and APIs. |
Key management Mr. Govardhan M. Dhoot (Chairman & Managing Director), Mr. Brijmohan M. Dhoot (Whole-time Director). |
Our journey and innovations Since 1972, expanded product range, increased capacity, and gained WHO approvals including key anti-malaria APIs like Lumefantrine. |
Where we operate India (Gujarat, Maharashtra) with domestic and export markets contributing to revenues. |
Top products or what we offer APIs like Chloroquine phosphate, Lumefantrine, Sulfadoxine, Nimesulide; bulk drugs and chemical intermediates. |
Top brands - |
Raw materials needed Key raw materials for APIs, including intermediates and chemicals, some previously imported from China. |
Raw materials supplier Multiple suppliers; recently enhanced in-house production to reduce import dependence. |
Recurring vs cyclical contribution Revenue is largely recurring from ongoing API and bulk drug supply contracts. |
Our industry position Mid-sized API manufacturer with WHO certifications, niche anti-malaria API portfolio, recognized by global health bodies. |
Financial highlights FY2024-25 revenue Rs 318.23 Crores; net profit Rs 6.72 Crores; improved profitability after prior losses. |
Geographical revenue split Domestic operations contribute roughly 81%, exports about 19% of revenues. |
Order book - |
Whats driving growth New anti-malaria API launches, WHO prequalification, collaboration with health foundations, and enhanced in-house manufacturing. |
Our future plans Expand production capacity for key APIs, strengthen R&D, and grow anti-malaria product portfolio globally. |
Our green promise - |
Our people and values Committed workforce with focus on ethical practices, safety, and compliance across operations. |
Key challenges ahead Raw material cost volatility, regulatory compliance, competition, and sustaining innovation. |
Interesting facts WHO approvals for multiple APIs; collaboration with Bill & Melinda Gates Foundation on malaria treatments. |
Risks and strategy Mitigating supply chain risks via in-house raw material production; diversification of product portfolio and markets. |
